Active not recruiting
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
I4T-MC-JVDC - ClinicalTrials.gov - NCT02426125
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
How long will I be in the trial?
Participation in this trial could last up to 12 months, depending on how you and your tumor respond
Active not recruiting
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
I4T-MC-JVDC - ClinicalTrials.gov - NCT02426125
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
How long will I be in the trial?
Participation in this trial could last up to 12 months, depending on how you and your tumor respond
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis confirmed by histology or cytology
Participant must have disease progression while on a platinum containing regimen in the first-line setting or within 14 months after completing the first-line platinum regimen
Participant must be willing to provide blood, urine, and tissue samples for research purposes
Participants must NOT
Participant must not have received more than one prior systemic chemotherapy regimen for metastatic disease
Participant must not have received radiation therapy within 4 weeks (≤4 weeks) prior to first dose of study drug or has not recovered from toxic effects of the treatment that was given >4 weeks prior to first dose of study drug
Participant must not have a concurrent malignancy or had another malignancy within 5 years (≤5 years) of study enrollment
Participant must not have HIV infection or acquired immunodeficiency syndrome-related illness
Participant must not be pregnant or lactating
Trial Summary
Conditions the trial is for
Urothelial Cancer
What the trial is testing?
Ramucirumab, Docetaxel, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
524
Trial Dates
July 2015 - June 2021
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis confirmed by histology or cytology
Participant must have disease progression while on a platinum containing regimen in the first-line setting or within 14 months after completing the first-line platinum regimen
Participant must be willing to provide blood, urine, and tissue samples for research purposes
Participants must NOT
Participant must not have received more than one prior systemic chemotherapy regimen for metastatic disease
Participant must not have received radiation therapy within 4 weeks (≤4 weeks) prior to first dose of study drug or has not recovered from toxic effects of the treatment that was given >4 weeks prior to first dose of study drug
Participant must not have a concurrent malignancy or had another malignancy within 5 years (≤5 years) of study enrollment
Participant must not have HIV infection or acquired immunodeficiency syndrome-related illness
Participant must not be pregnant or lactating
Trial Summary
Conditions the trial is for
Urothelial Cancer
What the trial is testing?
Ramucirumab, Docetaxel, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
524
Trial Dates
July 2015 - June 2021
Trial Phase
3
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Urothelial Cancer Resources
